Clindamycin

Generic Name: Clindamycin

Brand Names: Acanya, Benzaclin, Biacna, Cabtreo, Cleocin, Cleocin-T, Clindacin, Clindagel, Clindesse, Clindoxyl, Dalacin, Dalacin C, Duac, Evoclin, Neuac, Onexton, Veltin, Xaciato, Ziana

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₃ClN_₂O_₅S

CAS Number: 18323-44-9

Unique Ingredient Identifier: 3U02EL437C

Background: Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamy...

Indication: In oral and parenteral formulations, clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria, as well as susceptible staphylococci, streptococci, and pneumococci. Used topically, it is indicated for the treatment of acne vulgaris and is available in combination with benzoyl peroxide or tretinoin for this purp...

Associated Conditions: Abscess, Intra-Abdominal caused by Anaerobic Bacterial Infection, Acne Vulgaris, Babesiosis, Bacterial Endocarditis, Bacterial Vaginosis (BV), Bloodstream Infections caused by Anaerobic Bacterial Infection, Bone and Joint Infections caused by susceptible Staphylococcus, Empyema caused by Anaerobic Bacterial Infection, Endometritis caused by Anaerobic Bacterial Infection, Lung Abscess caused by Anaerobic Bacterial Infection, Malaria caused by Plasmodium falciparum, Mixed Vaginal Infections, Pelvic cellulitis caused by Anaerobic Bacterial Infection, Peritonitis caused by Anaerobic Bacterial Infection, Pneumocystis Jirovecii Pneumonia, Pneumonitis caused by Anaerobic Bacterial Infection, Respiratory Tract Infections (RTI) caused by susceptible Staphylococcus, Respiratory Tract Infections (RTI) caused by susceptible pneumococci, Respiratory Tract Infections (RTI) caused by susceptible streptococci, Septicemia caused by susceptible Staphylococcus, Septicemia caused by susceptible streptococci, Skin Structures and Soft Tissue Infections caused by Anaerobic Bacterial Infection, Skin Structures and Soft Tissue Infections caused by susceptible Staphylococcus, Skin Structures and Soft Tissue Infections caused by susceptible streptococci, Toxoplasmosis, Tubo-ovarian abscess caused by Anaerobic Bacterial Infection, Vaginal Candidiasis, Vaginal Mycosis, Chronic Bone and Joint Infections caused by Susceptible infections, Moderate Acne vulgaris, Post-surgical vaginal cuff infection caused by Anaerobic Bacterial Infection, Viridans group streptococci

Associated Therapies: -

Clinical Trials

Staphylococcus Aureus Network Adaptive Platform Trial

Phase 4

Recruiting

Conditions: Staphylococcus Aureus Bacteremia

Interventions: Radiation: Whole body FDG PET/CT Imaging
Drug: Penicillin
Other: Effectiveness of early switch to oral antibiotics
Drug: Cefazolin
Drug: Clindamycin
Drug: Vancomycin

First Posted Date: 2021-11-30

Last Posted Date: 2024-06-05

Lead Sponsor: University of Melbourne

Target Recruit Count: 8000

Registration Number: NCT05137119

Locations: 🇦🇺
Cairns Hospital, Cairns, Queensland, Australia
🇨🇦
Hôpital Régional de Saint Jérôme, Saint-Jérôme, Quebec, Canada
🇳🇱
Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands

and more 146 locations

Or v IV Antibiotics for Infection

Phase 3

Conditions: Joint Infection

Interventions: Drug: Bactrim
Drug: Cefadroxil
Drug: Doxycycline Hcl
Drug: Clindamycin

First Posted Date: 2021-01-26

Last Posted Date: 2021-01-26

Lead Sponsor: Rothman Institute Orthopaedics

Target Recruit Count: 308

Registration Number: NCT04723940

Locations: 🇺🇸
Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States

A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting

Phase 4

Completed

Conditions: Burn
Surgery
Infection Wound

Interventions: Drug: Cefazolin
Drug: Clindamycin

First Posted Date: 2020-08-18

Last Posted Date: 2022-08-26

Lead Sponsor: Medstar Health Research Institute

Target Recruit Count: 32

Registration Number: NCT04516148

Locations: 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

Phase 4

Active, not recruiting

Conditions: Bladder Carcinoma
Urinary Tract Infection
Refractory Bladder Carcinoma

Interventions: Drug: Clindamycin
Drug: Ertapenem
Other: Diary
Drug: Levofloxacin
Drug: Nitrofurantoin
Drug: Trimethoprim-Sulfamethoxazole

First Posted Date: 2020-08-06

Last Posted Date: 2024-07-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 89

Registration Number: NCT04502095

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Phase 2

Recruiting

Conditions: Skin Toxicity
Glioblastoma
Recurrent Glioblastoma

Interventions: Drug: Clindamycin Phosphate
Drug: Triamcinolone Acetonide

First Posted Date: 2020-07-13

Last Posted Date: 2024-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT04469075

Locations: 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 5 locations

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Clindamycin Phosphate
Drug: Clindamycin Phosphate RLD
Drug: Placebos

First Posted Date: 2020-03-25

Last Posted Date: 2020-03-25

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 550

Registration Number: NCT04321070

Locations: 🇺🇸
Catawba Research LLC, Charlotte, North Carolina, United States

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Placebo
Drug: CLPG Topical Gel 1%
Drug: Clindamycin

First Posted Date: 2019-10-22

Last Posted Date: 2019-10-22

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1260

Registration Number: NCT04134273

Locations: 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States

Optimal Treatment of MRSA Throat Carriers

Phase 3

Recruiting

Conditions: MRSA
MRSA Colonization

Interventions: Drug: Clindamycin
Drug: Placebo

First Posted Date: 2019-09-26

Last Posted Date: 2024-06-11

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 80

Registration Number: NCT04104178

Locations: 🇩🇰
Hvidovre Hospital, Hvidovre, Denmark

Laser Therapy for Perioral Dermatitis

Not Applicable

Withdrawn

Conditions: Perioral Dermatitis

Interventions: Drug: Clindamycin

First Posted Date: 2018-12-19

Last Posted Date: 2022-03-03

Lead Sponsor: West Virginia University

Registration Number: NCT03779295

Locations: 🇺🇸
West Virginia University University Town Centre Dermatology Clinic, Morgantown, West Virginia, United States

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

First Posted Date: 2018-04-27

Last Posted Date: 2024-12-17

Lead Sponsor: Duke University

Target Recruit Count: 1600

Registration Number: NCT03511118

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Loma Linda University Health, Loma Linda, California, United States

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy